B2BROKER
28.1.2020 11:15:06 CET | Business Wire | Press release
B2Broker, a leading liquidity and technology provider of solutions to the Forex and crypto industry, has signed an agreement with Devexperts , a financial software developer, to license their dxTrade platform. dxTrade is a multi-asset trading solution for brokers which, unlike other existing OTC trading platforms, supports the entire spectrum of assets. This feature will allow B2Broker to become the leading Prime of Prime liquidity provider in the industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200128005354/en/
B2Broker’s pool of trading platforms currently includes OneZero Hub, PrimeXM xCore, several MT4 and MT5 trading platforms, together with B2Trader (the company’s own Matching Engine platform). With the addition of dxTrade, clients will be able to gain quick and easy access to one of the deepest liquidity pools in the industry for Stocks/Equities, ETFs, CFDs, Futures, Vanilla Options, Commodities, Metals, Forex, Crypto Futures, Crypto Spot, Crypto CFD and Bonds.
The company, which recently expanded its Crypto CFD liquidity offering with the addition of 61 new crypto pairs, now totalling 100 pairs, is recognised as being one of the industry’s leading LPs, offering the highest level of support with 24/7 trading and support in English, Russian, Chinese Cantonese and Simplified, Arabic, Spanish, Hindu, Italian, Urdu, Farsi, Pashto, Hebrew and Turkish.
B2Broker recently completed its integration with the dxTrade platform in order to spread liquidity amongst brokers who already use dxTrade, and to offer it to newly established or expanding brokers. From now on, they will be able to connect to one of the largest liquidity pools in the industry in just one minute through FIX API or by connecting to dxTrade directly.
Moreover, B2Broker has integrated B2Core with dxTrade. B2Core, the new name for Trader’s Room , is a ready-made functional solution for brokerages which allows clients to verify and register customers and perform functions such as accepting and sending payments, make deposits and withdrawals and open accounts, etc. Companies who use the dxTrade platform can quickly get connected to B2Core prior to launching their own brokerage business.
Finally, the company’s cryptocurrency payment gateway, B2BinPay , has also been integrated with dxTrade, enabling clients to securely and cost-effectively send, receive, store, exchange and accept cryptocurrency payments online.
Arthur Azizov, Founder and CEO of B2Broker commented, “Our goal to become a global Prime of Prime liquidity provider became a reality thanks to our tailored version of dxTrade which, in combination with our technology and depth of liquidity, makes our offering unmatchable in the industry.”
Evgeny Sorokin, SVP of Software Engineering, Devexperts added: “We are pleased that B2Broker has chosen our modular multi-asset trading platform. dxTrade can be configured to serve different clients in different markets and I am certain that our technology will assist B2Broker with their expansion.”
About B2Broker
B2Broker is a liquidity and technology provider of solutions for the crypto and foreign exchange industry. The company specialises in the sphere of B2B services and products, catering for a wide range of clients including large licensed brokers, crypto exchanges, crypto brokers, forex brokers, hedge and crypto funds and professional managers.
B2Broker’s advanced base of ready to use technical solutions enable brokers to save time and money on consuming infrastructure projects and focus on enlarging their client base and increasing their revenues.
About Devexperts
Devexperts specializes in the development of tailored software solutions for the Capital Markets industry with clients including retail and institutional brokerage houses, exchanges, and wealth management firms. Devexperts are the developers of the thinkorswim platform and numerous recognized and reliable financial applications, with millions of traders using their technology daily. The services from Devexperts include low-latency market data feeds, AR/VR data visualization, AI digital assistants, deep learning, and market analysis.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200128005354/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis26.6.2026 13:30:00 CEST | Press release
If approved, Opzelura® (ruxolitinib) cream will be the first steroid-free, topical JAK treatment option in the European Union (EU) for adults with moderate atopic dermatitis (AD) for whom standard topical therapies have failedAD, the most common type of eczema which affects 230 million people globally,1 is a chronic, recurring, inflammatory and highly pruritic (itchy) skin condition that can have a significant impact on daily life2Phase 3 TRuE‑AD4 data supporting the positive CHMP opinion demonstrated that ruxolitinib cream met both co‑primary endpoints at Week 8, maintained disease control with as-needed treatment through Week 24 and was well tolerated3,4,5 Incyte (Nasdaq: INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Opzelura® (ruxolitinib) cream for the treatment of moderate atopic dermatitis (AD) in adult patients for whom topical corticosteroids
Datroway® Recommended for Approval in the EU by CHMP as First-Line Treatment for Patients with Metastatic Triple Negative Breast Cancer Who Are Not Candidates for Immunotherapy26.6.2026 13:00:00 CEST | Press release
Recommendation based on TROPION-Breast02 phase 3 trial where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival If approved, Datroway has potential to be the first TROP2 directed antibody drug conjugate for patients in EU with a demonstrated overall survival benefit as first-line treatment Datroway® (datopotamab deruxtecan) has been recommended for approval in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use
DAYBU®(trofinetide) Recommended for Approval in the European Union by CHMP26.6.2026 12:49:00 CEST | Press release
-- European Commission decision expected in the coming months-- If approved, DAYBU®would become the first treatment for neurobehavioral symptoms of Rett syndrome in the European Union Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion following a re-examination procedure, recommending the granting of a marketing authorization for DAYBU® (trofinetide) for the treatment of neurobehavioral symptoms of Rett syndrome in adults and pediatric patients aged five years and older. If granted marketing authorization by the European Commission, DAYBU® would be the first therapy approved for this indication in the European Union (EU). “The CHMP’s positive opinion for DAYBU® is an important milestone in our mission to bring this innovative therapy to the EU, where there are no therapies specifically approved for the neurobehavioral symptoms of this devastating
HTEC Showcases Lakebase Branching at Databricks’ Data & AI Summit26.6.2026 11:18:00 CEST | Press release
HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. The Solution was developed in collaboration with a leading risk and compliance technology provider who serves financial institutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260626875859/en/ HTEC, the global technology and AI engineering firm headquartered in Silicon Valley, last week showcased how it used Lakebase data branching to enable faster development, safer operations, and new possibilities for data-driven organizations operating in highly regulated environments. Solving Critical Development Bottlenecks in Regulated Environments At the core of the collaboration was a shared challenge: how to enable modern data workflows in an envi
Stallergenes Greer Named One of Switzerland’s Best Managed Companies for 202626.6.2026 10:28:00 CEST | Press release
Stallergenes Greer, a global leader in allergy care, has been recognised for its overall business performance, company culture, and sustained growth by receiving the prestigious 2026 Switzerland’s Best Managed Companies award. The 2026 Best Managed Companies programme award winners are among Switzerland’s best private companies. The awards are derived from Deloitte’s global Best Managed Companies awards programme, an internationally recognised programme that evaluates businesses based on their leadership in the areas of strategy, culture and commitment, capabilities, innovation, governance and financial performance. Applicants are evaluated by an independent jury of experts. The evaluation of the Switzerland awards is based on more than 30 years of observed practice from the global awards programme that has been rolled out in 50+ countries worldwide. This recognition reflects Stallergenes Greer's consistent ability to deliver on its strategic vision while maintaining the operational di
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom